Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors

Olaratumab is a monoclonal antibody that specifically binds to platelet‐derived growth factor receptor alpha (PDGFRα) and blocks receptor activation. We conducted a phase 1 trial to evaluate the safety of olaratumab and determine a recommended dose in combination with three different chemotherapy re...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Med
Hlavní autoři: Mascarenhas, Leo, Ogawa, Chitose, Laetsch, Theodore W., Weigel, Brenda J., Bishop, Michael W., Krystal, Julie, Borinstein, Scott C., Slotkin, Emily K., Muscal, Jodi A., Hingorani, Pooja, Levy, Donna E., Mo, Gary, Shahir, Ashwin, Wright, Jennifer, DuBois, Steven G.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2021
Témata:
Clinical Cancer Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7897905/
https://ncbi.nlm.nih.gov/pubmed/33474828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3658
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky